When Resolving Minor Differences in Protein Therapeutics Can Have a Major Impact

,

Scientists from Waters and Pfizer collaborated to take on the challenge of engineering a novel reversed-phase LC column for high-throughput separations with enhanced resolution, selectivity, and recovery of target mAbs and ADCs.